PEPG Stock Overview
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
PepGen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.38 |
| 52 Week High | US$17.81 |
| 52 Week Low | US$4.32 |
| Beta | 0 |
| 1 Month Change | 4.06% |
| 3 Month Change | 43.07% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19.32% |
Recent News & Updates
Shareholder Returns
| PEPG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | -0.8% | 1.7% |
| 1Y | n/a | 4.4% | -9.6% |
Return vs Industry: Insufficient data to determine how PEPG performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PEPG performed against the US Market.
Price Volatility
| PEPG volatility | |
|---|---|
| PEPG Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PEPG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: PEPG's weekly volatility has decreased from 23% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 40 | James McArthur | https://www.pepgen.com |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company’s lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
PepGen Inc. Fundamentals Summary
| PEPG fundamental statistics | |
|---|---|
| Market Cap | US$363.46m |
| Earnings (TTM) | -US$61.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.9x
P/E RatioIs PEPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEPG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$61.31m |
| Earnings | -US$61.31m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.59 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PEPG perform over the long term?
See historical performance and comparison